The Insight Partners published latest research report on “Male Infertility Market Size Report, Share, Trends, Growth & Key Companies Forecast to 2027 - COVID-19 Impact and Global Analysis by Test; Treatment Type; Distribution Channel
The Insight Partners published latest research report on “Male Infertility Market Size Report, Share, Trends, Growth & Key Companies Forecast to 2027 - COVID-19 Impact and Global Analysis by Test; Treatment Type; Distribution Channel; End User, and Geography”, the global market is expected to reach USD 6,213.96 million by 2027 from USD 3,883.82 million in 2019; it is estimated to grow at a CAGR of 6.2% from 2020 to 2027.
Request Sample PDF Brochure: https://www.theinsightpartners.com/sample/TIPRE00007061
Growth Strategies by the Key Players Operating in the Male Infertility Market:
Jul 19 - Vitrolife entered into a collaboration agreement with Prime Tech for developing and exclusively market the Piezo technique for enhanced ICSI procedure in human IVF of Vitrolife in the global markets, excluding the countries such as Japan, Thailand, and Malaysia. Vitrolife has initiated regulatory approval for various markets to enable prospective commercialization of the technology
Apr 18 - Hamilton Thorne and Halotech DNA partnered to expand the products and services related to reproductive technologies. This partnership is focused on the business expansion, including the collaboration of Halotech DNA’s in-vitro diagnostic kit-related products Halosprm G2 kit and compatibility the Hamilton Thorne’s IVOS II and CEROS II DNA Fragmentation module.
Male infertility is due to low sperm production, abnormal sperm function or blockages that prevent the delivery of sperm. Illnesses, injuries, chronic health problems, lifestyle choices such as Smoking, drinking alcohol, and taking certain medications can lower sperm numbers. Other causes of low sperm numbers include long-term sickness (such as kidney failure), childhood infections (such as mumps), and chromosome or hormone problems (such as low testosterone). In over a third of infertility cases, the problem is with the man. This is most often due to problems with the sperm production or with sperm delivery.
Directly Purchase Premium Copy of Male Infertility Market Growth Report (2020-2027) at: https://www.theinsightpartners.com/buy/TIPRE00007061
Global Male Infertility Market Share Report, Segmentations, Regional & Country Scope:
| Report Coverage | Details |
| Market Size Value in | USD 3,883.82 Million in 2019 |
| Market Size Value by | USD 6,213.96 Million by 2027 |
| Growth rate | CAGR of 6.2% from 2020-2027 |
| Forecast Period | 2020-2027 |
| Base Year | 2020 |
| No. of Pages | 280 |
| No. of Tables | 221 |
| No. of Charts & Figures | 90 |
| Historical data available | Yes |
| Segments covered | Test; Treatment Type; Distribution Channel; End User, and Geography |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country scope | US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Companies Covered | MERCK KGaA, Sanofi, Bayer AG, Endo Pharmaceuticals Inc., SCSA Diagnostics, Inc., Andrology Solutions, Halotech DNA, INTAS PHARMACEUTICALS LTD., Cadila Pharmaceuticals Ltd., Vitrolife |
| Key Research Capabilities | Global Market Assessment, Business Development Strategies, Competitive Landscape, Opportunity Analysis, Regional and Country Level Market Analysis, Market Entry Strategies, Market Dynamics, Risk and Return Assessments, Pricing Analysis, Market Size and Forecasting, Company Profiling, Value Chain Analysis, Expansion Strategies, SWOT Analysis, New Product Development |
Browse key market insights spread across 280 pages with 221 list of tables & 90 list of figures from the report, “Male Infertility Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Test (DNA Fragmentation Technique, Oxidative Stress Analysis, Microscopic Examination, Sperm Agglutination, Computer Assisted Semen Analysis, Sperm Penetration Assay, Others); Treatment Type (Assisted Reproductive Technology, Varicocele Surgery, Medication); Distribution Channel (Hospitals Pharmacies, Pharmacies and Drug Stores, Online Pharmacies); End User (Hospitals and Clinics, Fertility Centers, Research Institutes, Other End Users), and Geography” in detail along with the table of contents: https://www.theinsightpartners.com/reports/male-infertility-market
According to the World Health Organization (WHO), among ~20% of infertile couples, the problem is with male partners, whereas in 30% of couples, the issue exists in both the partners. Thus, men contribute to ~50% of the infertility cases globally. Furthermore, according to Healthy Male Andrology Australia, a division funded by Australian Government Department of Health, ~1 in 20 males produces low number of sperms, leading to infertility, and 1 in ~100 men has no sperms at all.
Infertility in males is a global issue with prevalence percentages varying from one region to another. Deficiencies in semen and poor semen quality are the prime causes of infertility in men. According to the National Institutes of Health (NIH), infertility affected ~15% couples, i.e., ~48.5 million couples, worldwide in 2016. Further, according to a research survey published in the Journal of Reproductive Biology and Endocrinology, in 2016, infertility rate among men was found to be highest in Africa and Eastern/Central Europe.
The standardization of regulations in majority of countries has helped the male infertility market players to launch their innovative solutions. For instance, in January 2016, AytuBioScience obtained the CE mark for MiOXSYS System that assesses the levels of oxidative stress in human semen, thereby aiding in the diagnosis of infertility. Similarly, in October 2016, Episona Inc., an epigenetics data company focused on improving outcomes in reproductive health, introduced an innovative male infertility test named Seed. The test evaluates epigenetic changes on DNA to predict the male infertility and poor embryo development risks. Further, in January 2019, Dadi, a men’s health company, launched at-home fertility test and sperm storage kit, making the male reproductive health issues more accessible.
The Centers for Disease Control and Prevention (CDC), WHO, European Union (EU), Organization for Economic Co-operation and Development, Office for National Statistics, and National Health Service (NHS) are a few of the essential secondary sources referred to while preparing this report.
Go through further research published by The Insight Partners: (Purchase with 10% Instant Discount):
Infertility Testing Market Forecast to 2028 - Covid-19 Impact and Global Analysis
Infertility Drugs Market Forecast to 2028 - Covid-19 Impact and Global Analysis
Infertility Treatment Devices and Equipment Market Forecast to 2027 - COVID-19 Impact and Global Analysis
Infertility Testing and Treatment Market Forecast to 2028 - Covid-19 Impact and Global Analysis
Fertility Services Market Forecast to 2028 - Covid-19 Impact and Global Analysis
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/male-infertility-market